Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives

Mark P. Little; Wei Zhang; Roy van Dusen; Nobuyuki Hamada; Michelle Bugden; Meiyun Cao; Kiersten Thomas; Deyang Li; Yi Wang; Megha Chandrashekhar; Mohammad K. Khan; C. Norman Coleman

doi:10.1080/09553002.2022.2074165

Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives

Mark P. Little^*
, Wei Zhang
, Roy van Dusen
, Nobuyuki Hamada
, Michelle Bugden
, Meiyun Cao
, Kiersten Thomas
, Deyang Li
, Yi Wang
, Megha Chandrashekhar
, Mohammad K. Khan
, C. Norman Coleman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The lessons learned from the Coronavirus Disease 2019 (COVID-19) pandemic are numerous. Low dose radiotherapy (LDRT) was used in the pre-antibiotic era as treatment for bacterially/virally associated pneumonia. Motivated in part by these historic clinical and radiobiological data, LDRT for treatment of COVID-19-associated pneumonia was proposed in early 2020. Although there is a large body of epidemiological and experimental data pointing to effects such as cancer at low doses, there is some evidence of beneficial health effects at low doses. It has been hypothesized that low dose radiation could be combined with immune checkpoint therapy to treat cancer. We shall review here some of these old radiobiological and epidemiological data, as well as the newer data on low dose radiation and stimulated immune response and other relevant emerging data. The paper includes a summary of several oral presentations given in a Symposium on “Low dose RT for COVID and other inflammatory diseases” as part of the 67th Annual Meeting of the Radiation Research Society, held virtually 3-6 October 2021.

Original language	English
Pages (from-to)	357-371
Number of pages	15
Journal	International Journal of Radiation Biology
Volume	99
Issue number	2
Early online date	26 May 2022
DOIs	https://doi.org/10.1080/09553002.2022.2074165
Publication status	Published - 2023

Bibliographical note

Publisher Copyright:
©, This work was authored as part of the Contributor's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 USC. 105, no copyright protection is available for such works under US Law.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Low dose radiotherapy
cancer risk
epidemiology
radiobiology

Access to Document

10.1080/09553002.2022.2074165

Cite this

Little, M. P., Zhang, W., van Dusen, R., Hamada, N., Bugden, M., Cao, M., Thomas, K., Li, D., Wang, Y., Chandrashekhar, M., Khan, M. K., & Coleman, C. N. (2023). Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives. International Journal of Radiation Biology, 99(2), 357-371. https://doi.org/10.1080/09553002.2022.2074165

@article{ff1c7d2853234779b3ca7e23a5873477,

title = "Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives",

abstract = "The lessons learned from the Coronavirus Disease 2019 (COVID-19) pandemic are numerous. Low dose radiotherapy (LDRT) was used in the pre-antibiotic era as treatment for bacterially/virally associated pneumonia. Motivated in part by these historic clinical and radiobiological data, LDRT for treatment of COVID-19-associated pneumonia was proposed in early 2020. Although there is a large body of epidemiological and experimental data pointing to effects such as cancer at low doses, there is some evidence of beneficial health effects at low doses. It has been hypothesized that low dose radiation could be combined with immune checkpoint therapy to treat cancer. We shall review here some of these old radiobiological and epidemiological data, as well as the newer data on low dose radiation and stimulated immune response and other relevant emerging data. The paper includes a summary of several oral presentations given in a Symposium on “Low dose RT for COVID and other inflammatory diseases” as part of the 67th Annual Meeting of the Radiation Research Society, held virtually 3-6 October 2021.",

keywords = "COVID-19, Low dose radiotherapy, cancer risk, epidemiology, radiobiology",

author = "Little, \{Mark P.\} and Wei Zhang and \{van Dusen\}, Roy and Nobuyuki Hamada and Michelle Bugden and Meiyun Cao and Kiersten Thomas and Deyang Li and Yi Wang and Megha Chandrashekhar and Khan, \{Mohammad K.\} and Coleman, \{C. Norman\}",

note = "Publisher Copyright: {\textcopyright}, This work was authored as part of the Contributor's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 USC. 105, no copyright protection is available for such works under US Law.",

year = "2023",

doi = "10.1080/09553002.2022.2074165",

language = "English",

volume = "99",

pages = "357--371",

journal = "International Journal of Radiation Biology",

issn = "0955-3002",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

Little, MP, Zhang, W, van Dusen, R, Hamada, N, Bugden, M, Cao, M, Thomas, K, Li, D, Wang, Y, Chandrashekhar, M, Khan, MK & Coleman, CN 2023, 'Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives', International Journal of Radiation Biology, vol. 99, no. 2, pp. 357-371. https://doi.org/10.1080/09553002.2022.2074165

TY - JOUR

T1 - Low-dose radiotherapy for COVID-19 pneumonia and cancer

T2 - summary of a recent symposium and future perspectives

AU - Little, Mark P.

AU - Zhang, Wei

AU - van Dusen, Roy

AU - Hamada, Nobuyuki

AU - Bugden, Michelle

AU - Cao, Meiyun

AU - Thomas, Kiersten

AU - Li, Deyang

AU - Wang, Yi

AU - Chandrashekhar, Megha

AU - Khan, Mohammad K.

AU - Coleman, C. Norman

N1 - Publisher Copyright: ©, This work was authored as part of the Contributor's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 USC. 105, no copyright protection is available for such works under US Law.

PY - 2023

Y1 - 2023

N2 - The lessons learned from the Coronavirus Disease 2019 (COVID-19) pandemic are numerous. Low dose radiotherapy (LDRT) was used in the pre-antibiotic era as treatment for bacterially/virally associated pneumonia. Motivated in part by these historic clinical and radiobiological data, LDRT for treatment of COVID-19-associated pneumonia was proposed in early 2020. Although there is a large body of epidemiological and experimental data pointing to effects such as cancer at low doses, there is some evidence of beneficial health effects at low doses. It has been hypothesized that low dose radiation could be combined with immune checkpoint therapy to treat cancer. We shall review here some of these old radiobiological and epidemiological data, as well as the newer data on low dose radiation and stimulated immune response and other relevant emerging data. The paper includes a summary of several oral presentations given in a Symposium on “Low dose RT for COVID and other inflammatory diseases” as part of the 67th Annual Meeting of the Radiation Research Society, held virtually 3-6 October 2021.

AB - The lessons learned from the Coronavirus Disease 2019 (COVID-19) pandemic are numerous. Low dose radiotherapy (LDRT) was used in the pre-antibiotic era as treatment for bacterially/virally associated pneumonia. Motivated in part by these historic clinical and radiobiological data, LDRT for treatment of COVID-19-associated pneumonia was proposed in early 2020. Although there is a large body of epidemiological and experimental data pointing to effects such as cancer at low doses, there is some evidence of beneficial health effects at low doses. It has been hypothesized that low dose radiation could be combined with immune checkpoint therapy to treat cancer. We shall review here some of these old radiobiological and epidemiological data, as well as the newer data on low dose radiation and stimulated immune response and other relevant emerging data. The paper includes a summary of several oral presentations given in a Symposium on “Low dose RT for COVID and other inflammatory diseases” as part of the 67th Annual Meeting of the Radiation Research Society, held virtually 3-6 October 2021.

KW - COVID-19

KW - Low dose radiotherapy

KW - cancer risk

KW - epidemiology

KW - radiobiology

UR - https://www.scopus.com/pages/publications/85131169352

U2 - 10.1080/09553002.2022.2074165

DO - 10.1080/09553002.2022.2074165

M3 - Article

C2 - 35511152

AN - SCOPUS:85131169352

SN - 0955-3002

VL - 99

SP - 357

EP - 371

JO - International Journal of Radiation Biology

JF - International Journal of Radiation Biology

IS - 2

ER -

Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this